Anti-PD-L1 immune checkpoint inhibitors are widely used for last-stage malignant tumors, especially metastatic non-small cell lung carcinoma, clear cell renal cell carcinoma, breast cancer, and melanoma [20]. This evidence concerns the gene CD274 and cancer.